IBM
53
2
PBI
30
-8
LEN
21
3
MAT
41
2
PLD
35
5
ECL
54
5
DOW
47
4
MPC
28
3
EFX
43
3
EQR
33
6
STZ
42
2
COP
36
2
MAR
57
3
MET
58
2
JNPR
59
3
SIG
52
5
VRSK
54
2
EXPD
29
2
JPM
59
6
EW
55
5
IBM
53
2
PBI
30
-8
LEN
21
3
MAT
41
2
PLD
35
5
ECL
54
5
DOW
47
4
MPC
28
3
EFX
43
3
EQR
33
6
STZ
42
2
COP
36
2
MAR
57
3
MET
58
2
JNPR
59
3
SIG
52
5
VRSK
54
2
EXPD
29
2
JPM
59
6
EW
55
5
Financhill
Back

Sarepta Therapeutics 10K Form

Sell
36

SRPT
Sarepta Therapeutics

Last Price:
$118.99
Seasonality Move:
12.18%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SRPT News And Ratings

See the #1 stock for the next 7 days that we like better than SRPT

SRPT Financial Statistics

Sales & Book Value

Annual Sales: $1.2B
Cash Flow: $-108M
Price / Cash Flow: 0
Annual Sales: $12.79
Price / Book: 9.31

Profitability

EPS (TTM): 1.54000
Net Income (TTM): $121.8M
Gross Margin: $1.1B
Return on Equity: 12.48%
Return on Assets: 3.67%

Sarepta Therapeutics Earnings Forecast

Key Sarepta Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 28 years for SRPT is 87.91%.
  • The Selling, General & Administrative Expenses for SRPT have been equal to 38.76% of Gross Profit Margin.
  • The Research & Development expenses have been 70.57% of Revenue.
  • The Interest Expense is -4.11% of Operating Income.
  • The Net Earning history of SRPT is -43.11% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 14 years.

Sarepta Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SRPT
CUSIP: 803607
Website: sarepta.com

Debt

Debt-to-Equity Ratio: 1.01
Current Ratio: 3.84
Quick Ratio: 2.45

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 10.28

SRPT Technical Analysis vs Fundamental Analysis

Sell
36
Sarepta Therapeutics (SRPT) is a Sell

Is Sarepta Therapeutics a Buy or a Sell?